The Clinical Utility of Circulating Epstein-Barr Virus DNA Concentrations in NK/T-Cell Lymphoma: A Meta-Analysis

Table 2

Characteristics of the included studies.

Study	Design	Inclusion period	N	Median or mean age	Ann Arbor stage	Sample	Cut-off value		Treatment strategy	Extractable survival outcomes	Median follow-up (months)
							Pre-DNA	Post-DNA
Lei et al. [21]	R	1995–2001	26	61y^a	I–IV	Plasma	600	—	CT/RT/CT → RT	OS	13 (4.5–24.3)
Kim et al. [9]	R	2004–2007	47	48.5y^a	I–IV	Whole blood	Median	—	NR	OS	NR
Suzuki et al. [10]	P	2004–2007	32	55y^a	I–IV	Plasma	1000	—	CT/RT/CCRT/RT → CT	OS	NR
Wang et al. [11]	P	2007–2009	69	39y^a	I–II	Plasma	500	0	RT/RT → CT	OS, PFS	32
Y Ito 2012 (1)	P	NR	26	46.5y^a	NR	Plasma	10E5	—	CT	OS, CR, and ORR	NR
Y Ito 2012 (2)	P	NR	26	46.5y^a	NR	Whole blood	1000	—	CT	OS, CR, and ORR	NR
Kwong et al. [12]	P	2005–2012	54	52.5y^a	I–IV	Plasma	—	0	CT	OS	NR
Liu et al. [13]	R	2011–2014	109	40y^a	I–IV	Plasma	500	—	NR	PFS, ORR	NR
Kim et al. [14]	R	2005–2013	102	48y^a	I–IV	Whole blood	—	0	CT/CCRT/CT → RT	OS, PFS	47.2 (30–65.5)
Wang et al. [6]	P	2008–2014	68	47y^a	I–II	Plasma	0	0	CT → RT	OS, PFS, and CR	32 (2–76)
Lim et al. [15]	R	2009–2014	27	44y^a	I–IV	Whole blood	—	0	CCRT	OS, PFS	36.9 (1.6–75.4)
Liang et al. [15]	R	2007–2012	13	43.5y^a	I–IV	Plasma	Median	—	CT/RT/CCRT/CT → RT/RT → CT	OS	NR
Yang et al. [17]	R	2006–2016	81	41y^a	I–IV	Plasma	500	—	CT/CT → RT/RT → CT	OS,PFS	21 (1–123)
Zhang et al. [23]	P	2010–2014	85	38.66y^b	I–IV	Plasma	0	—	CT → RT	OS, PFS, CR, and ORR	NR
Liang et al. [18]	P	2010–2015	32	48y^a	III–IV	Whole blood	5000	—	CT	OS, PFS, and ORR	NR

R: retrospective study; P: prospective study; NR: not reported; N: number of participants; pre-DNA: pretreatment EBV-DNA; post-DNA: posttreatment EBV-DNA; CT: chemotherapy; RT: radiotherapy; CCRT: concurrent chemoradiotherapy; OS: overall survival; PFS: progression-free survival; CR: complete response; ORR: overall response rate. ^aMedian age. ^bMean age.